A Phase-2 Study On The Efficacy Of Low-Dose Anandamide Plus A Neuroendocrine Regimen With High-Dose Melatonin And Low-Dose Angiotensin 1-7 In Patients Affected By Untreatable Glioblastoma
Abstract
Glioblastoma (GBM) still represents the most aggressive human neoplasm. The recent advances in the area of psychoneuroendocrinoimmunology (PNEI) have demonstrated that GBM is under a neuroendocrine regulation, since it has been shown to be stimulated by mu-opioid agonists and to be inhibited by the pineal hormones melatonin (MLT) and 5-methoxytryptamine (5-MTT), the cannabinoid agents, particularly cannabigerol (CBG), and angiotensin 1-7 (Ang 1-7). Moreover, preliminary clinical studies have suggested the potential efficacy of a neuroendocrine regimen consisting of MLT, 5-MTT, CBG, and Ang 1-7 in GBM patients progressed under the standard therapy with radiotherapy plus temozolomide. On these bases, a preliminary study was planned to evaluate the efficacy of the administration of the endogenous CB1-agonist anandamide in GBM patients, who progressed under both the conventional therapy and the neuroendocrine regimen with pineal hormones, Ang 1-7 and CBG. All drugs were given orally, MLT at 100 mg/day in the night, 5-MTT at 20 mg/day in the early afternoon, Ang 1-7 at 0.5 mg twice/day, CBG at 20 mg twice/day, and AEA at 0.5 mg/day in the morning. No complete response was observed. A partial response (PR) was achieved in one patient. Moreover, a stable disease (SD) occurred in 7 patients. Then, the percentage of disease control (PR + SD) was 8/14 (57%). Finally, a survival longer than 1 year was achieved in 5/14 (36%). No toxicity was observed. On the contrary, patients improved their mood and status of consciousness, and 5 of them referred a status of bliss. The results of this preliminary study would suggest a potential therapeutic role of AEA in GMB, also in patient with very advanced disease already under therapy with exogenous cannabinoids.